Company Name, Ticker, Suppliers, else..

Worst Performing Stocks In Healthcare Sector Today

1 Day

Week

Current Month of March

30 Days

Current Quarter Q1 of 2025

90 Days

Ytd

12 Months

Shares declined by -0.66% on average, in Healthcare Sector today.

Here are the Worst performing stocks in Healthcare Sector.

JAGX

$0.242

$-0.2270

-48.40%
Today's

JAGX

$0.242

$-0.2270

-48.40%

Jaguar Health Inc

Jaguar Health Inc stock dropped -48.40% today.

Jaguar Health Inc*s business model revolves around developing and commercializing natural, plant-based products for human and animal health. They aim to provide innovative solutions utilizing their scientific expertise in the development of novel medicines and consumer healthcare products.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 2.268 mill.	$ 10.480 mill.	$ -38.326 mill.	9 mill.	-	Y/Y 10.49 %

Market Cap.	Revenues TTM	Net Income TTM
$ 2.268 mill.	$ 10.480 mill.	$ -38.326 mill.
Employees	Shares Outstanding	P/E
64	9 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 10.49 %	MRQ Y/Y - %

RGBP

$0.0439

$-0.0282

-39.11%
Today's

RGBP

$0.0439

$-0.0282

-39.11%

Regen Biopharma Inc

Regen Biopharma Inc stock went down -39.11% today.

Regen Biopharma Inc is a biotechnology company that focuses on developing innovative treatments for diseases like cancer and autoimmune disorders. Their business model revolves around conducting research and development activities to create novel therapeutics and licensing or partnering with larger pharmaceutical companies for further development and commercialization. By leveraging their scientific expertise and strategic collaborations, Regen Biopharma aims to bring cutting-edge medical solutions to the market and improve patient outcomes.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.185 mill.	$ 0.154 mill.	$ -0.860 mill.	4 mill.	15.14	Y/Y 86.68 %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.185 mill.	$ 0.154 mill.	$ -0.860 mill.
Employees	Shares Outstanding	P/E
5	4 mill.	15.14
Revenue Growth	Income Growth
MRQ Y/Y 86.68 %	MRQ Y/Y - %

GYRE

$8.63

$-3.6500

-29.72%
Today's

GYRE

$8.63

$-3.6500

-29.72%

Gyre Therapeutics Inc

Gyre Therapeutics Inc shares dropped -29.72% today.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 885.786 mill.	$ 77.885 mill.	$ 17.329 mill.	103 mill.	172.60	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 885.786 mill.	$ 77.885 mill.	$ 17.329 mill.
Employees	Shares Outstanding	P/E
15	103 mill.	172.60
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

HYPR

$0.91

$-0.3700

-28.91%
Today's

HYPR

$0.91

$-0.3700

-28.91%

Hyperfine Inc

Hyperfine Inc shares dropped -28.91% today.

Hyperfine Inc operates on a business model that focuses on designing and manufacturing portable and affordable magnetic resonance imaging (MRI) systems, enabling medical professionals to access advanced imaging technology at a lower cost, expanding the reach of MRI diagnostics.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 66.138 mill.	$ 10.189 mill.	$ -41.087 mill.	73 mill.	-	Y/Y 18.99 %

Market Cap.	Revenues TTM	Net Income TTM
$ 66.138 mill.	$ 10.189 mill.	$ -41.087 mill.
Employees	Shares Outstanding	P/E
140	73 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 18.99 %	MRQ Y/Y - %

VRPX

$0.1287

$-0.0403

-23.85%
Today's

VRPX

$0.1287

$-0.0403

-23.85%

Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals Inc stock went down -23.85% today.

Virpax Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing innovative non-opioid products to address the unmet needs in pain management. Their business model revolves around research, development, and commercialization of these non-opioid solutions to provide effective and safe pain relief options for patients.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.547 mill.	$ - mill.	$ -12.067 mill.	4 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.547 mill.	$ - mill.	$ -12.067 mill.
Employees	Shares Outstanding	P/E
6	4 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

SANA

$2.28

$-0.4900

-17.69%
Today's

SANA

$2.28

$-0.4900

-17.69%

Sana Biotechnology Inc

Sana Biotechnology Inc stock went down -17.69% today.

Sana Biotechnology Inc operates as a biotechnology company that focuses on developing and commercializing cellular therapies for various diseases. Their business model involves leveraging innovative technologies and collaborations with clinical and industry partners to develop advanced medical treatments.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 536.739 mill.	$ - mill.	$ -305.807 mill.	235 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 536.739 mill.	$ - mill.	$ -305.807 mill.
Employees	Shares Outstanding	P/E
300	235 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

TTOO

$0.1035

$-0.0216

-17.27%
Today's

TTOO

$0.1035

$-0.0216

-17.27%

T2 Biosystems Inc

T2 Biosystems Inc stock went down -17.27% today.

T2 Biosystems Inc operates on a business model centered around developing and commercializing innovative diagnostic solutions for medical purposes. Their technology relies on magnetic resonance for the detection of pathogens, toxins, and other molecules associated with various diseases. By offering rapid, accurate, and portable diagnostic capabilities, T2 Biosystems aims to improve patient outcomes and facilitate appropriate treatment decisions in healthcare settings.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1.852 mill.	$ 7.677 mill.	$ -42.954 mill.	18 mill.	-	Y/Y 34.85 %

Market Cap.	Revenues TTM	Net Income TTM
$ 1.852 mill.	$ 7.677 mill.	$ -42.954 mill.
Employees	Shares Outstanding	P/E
60	18 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 34.85 %	MRQ Y/Y - %

SGMO

$0.8592

$-0.1508

-14.93%
Today's

SGMO

$0.8592

$-0.1508

-14.93%

Sangamo Therapeutics Inc

Sangamo Therapeutics Inc stock declined -14.93% today.

Sangamo Therapeutics Inc is a biotechnology company that focuses on developing genomic medicines. Their business model revolves around utilizing gene-editing technology to create therapies for genetic and rare diseases. They engage in research, development, and commercialization of their proprietary technologies to deliver innovative treatments with the potential to transform patients* lives.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 184.148 mill.	$ 52.291 mill.	$ -136.127 mill.	214 mill.	-	Y/Y 425.77 %

Market Cap.	Revenues TTM	Net Income TTM
$ 184.148 mill.	$ 52.291 mill.	$ -136.127 mill.
Employees	Shares Outstanding	P/E
405	214 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 425.77 %	MRQ Y/Y - %

DMAC

$5.24

$-0.7500

-12.52%
Today's

DMAC

$5.24

$-0.7500

-12.52%

Diamedica Therapeutics Inc

Diamedica Therapeutics Inc stock dropped -12.52% today.

Diamedica Therapeutics Inc*s business model focuses on developing and commercializing innovative therapies to improve patient outcomes in areas of unmet medical needs.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 224.018 mill.	$ - mill.	$ -21.705 mill.	43 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 224.018 mill.	$ - mill.	$ -21.705 mill.
Employees	Shares Outstanding	P/E
25	43 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

OM

$0.519

$-0.0591

-10.22%
Today's

OM

$0.519

$-0.0591

-10.22%

Outset Medical Inc

Outset Medical Inc stock went down -10.22% today.

Outset Medical Inc*s business model revolves around the production and distribution of innovative medical devices for kidney dialysis. With a focus on patient-centric care, their flagship product Tablo simplifies dialysis and allows for it to be performed in various clinical settings, including hospitals, clinics, and homes. By offering a comprehensive solution that combines hardware, software, and support services, Outset Medical aims to improve the dialysis experience for both healthcare providers and patients.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 27.000 mill.	$ 113.564 mill.	$ -127.976 mill.	52 mill.	-	Y/Y 3.50 %

Market Cap.	Revenues TTM	Net Income TTM
$ 27.000 mill.	$ 113.564 mill.	$ -127.976 mill.
Employees	Shares Outstanding	P/E
480	52 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 3.50 %	MRQ Y/Y - %

RNA

$30.48

$-3.3500

-9.90%
Today's

RNA

$30.48

$-3.3500

-9.90%

Avidity Biosciences Inc

Avidity Biosciences Inc stock dropped -9.90% today.

Avidity Biosciences Inc*s business model revolves around developing and commercializing potential therapeutics using its proprietary AOC platform, which enables the targeted delivery of drugs to specific cells in the body.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 3,399.227 mill.	$ 10.272 mill.	$ -330.387 mill.	112 mill.	-	Y/Y -21.93 %

Market Cap.	Revenues TTM	Net Income TTM
$ 3,399.227 mill.	$ 10.272 mill.	$ -330.387 mill.
Employees	Shares Outstanding	P/E
136	112 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -21.93 %	MRQ Y/Y - %

DWTX

$5.49

$-0.6000

-9.85%
Today's

DWTX

$5.49

$-0.6000

-9.85%

Dogwood Therapeutics inc

Dogwood Therapeutics Inc shares declined -9.85% today.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 6.096 mill.	$ - mill.	$ -4.590 mill.	1 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 6.096 mill.	$ - mill.	$ -4.590 mill.
Employees	Shares Outstanding	P/E
13	1 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

HOTH

$1.06

$-0.1100

-9.40%
Today's

HOTH

$1.06

$-0.1100

-9.40%

Hoth Therapeutics Inc

Hoth Therapeutics Inc stock dropped -9.40% today.

Hoth Therapeutics Inc*s business model focuses on the development and commercialization of innovative therapies for dermatological disorders and other related conditions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 7.318 mill.	$ - mill.	$ -7.892 mill.	7 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 7.318 mill.	$ - mill.	$ -7.892 mill.
Employees	Shares Outstanding	P/E
11	7 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

OCGN

$0.5194

$-0.0532

-9.29%
Today's

OCGN

$0.5194

$-0.0532

-9.29%

Ocugen Inc

Ocugen Inc shares dropped -9.29% today.

Ocugen Inc*s business model is focused on the development and commercialization of innovative gene therapies to treat rare and underserved ocular diseases, with a particular emphasis on underserved patient populations. They aim to leverage their expertise in gene therapy and partnerships to advance novel treatments and bring them to market, ultimately improving the lives of patients in need.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 140.264 mill.	$ 4.055 mill.	$ -54.010 mill.	270 mill.	-	Y/Y -87.34 %

Market Cap.	Revenues TTM	Net Income TTM
$ 140.264 mill.	$ 4.055 mill.	$ -54.010 mill.
Employees	Shares Outstanding	P/E
47	270 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -87.34 %	MRQ Y/Y - %

SHPH

$0.4083

$-0.0417

-9.27%
Today's

SHPH

$0.4083

$-0.0417

-9.27%

Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings Inc shares dropped -9.27% today.

Shuttle Pharmaceuticals Holdings Inc is a pharmaceutical company that operates on a business-to-business (B2B) model. They develop and manufacture a wide range of pharmaceutical products and then distribute them to other companies or medical institutions for further distribution or use. Their primary focus is on ensuring the quality and effectiveness of their products while partnering with other entities to ensure their widespread availability in the market.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.973 mill.	$ - mill.	$ -9.187 mill.	2 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.973 mill.	$ - mill.	$ -9.187 mill.
Employees	Shares Outstanding	P/E
10	2 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ANNX

$2.505

$-0.2450

-8.91%
Today's

ANNX

$2.505

$-0.2450

-8.91%

Annexon Inc

Annexon Inc shares went down -8.91% today.

Annexon Inc operates with a business model focused on developing therapeutic drugs to target and treat autoimmune and neurodegenerative disorders. The company conducts extensive research and preclinical studies to identify specific molecules that modulate the immune system and protect against neuroinflammation. Utilizing partnerships and collaborations, Annexon Inc aims to advance its drug candidates through clinical trials and potential commercialization to address unmet medical needs in the healthcare industry.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 342.763 mill.	$ - mill.	$ -138.200 mill.	137 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 342.763 mill.	$ - mill.	$ -138.200 mill.
Employees	Shares Outstanding	P/E
71	137 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ORGS

$2.87

$-0.2800

-8.89%
Today's

ORGS

$2.87

$-0.2800

-8.89%

Orgenesis Inc

Orgenesis Inc stock dropped -8.89% today.

Orgenesis Inc operates under a business model focused on the development and commercialization of technologies related to cell and gene therapies. They collaborate with academic institutions and hospitals to identify potential therapies, and then use their expertise in advanced manufacturing and cell therapy technologies to scale production and develop clinical protocols. Through partnerships and licensing agreements, Orgenesis aims to bring these innovative therapies to market and improve the lives of patients with chronic diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 13.533 mill.	$ 0.989 mill.	$ 35.260 mill.	5 mill.	0.39	Y/Y 215.45 %

Market Cap.	Revenues TTM	Net Income TTM
$ 13.533 mill.	$ 0.989 mill.	$ 35.260 mill.
Employees	Shares Outstanding	P/E
146	5 mill.	0.39
Revenue Growth	Income Growth
MRQ Y/Y 215.45 %	MRQ Y/Y 148.75 %

HIMS

$31.645

$-3.0450

-8.78%
Today's

HIMS

$31.645

$-3.0450

-8.78%

Hims and Hers Health Inc

Hims And Hers Health Inc shares dropped -8.78% today.

Hims and Hers Health Inc*s business model is centered around providing direct-to-consumer telehealth services for a wide range of health and wellness needs.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 7,525.420 mill.	$ 1,476.135 mill.	$ 126.038 mill.	238 mill.	60.24	Y/Y 94.39 %

Market Cap.	Revenues TTM	Net Income TTM
$ 7,525.420 mill.	$ 1,476.135 mill.	$ 126.038 mill.
Employees	Shares Outstanding	P/E
398	238 mill.	60.24
Revenue Growth	Income Growth
MRQ Y/Y 94.39 %	MRQ Y/Y 1,990.36 %

SKYE

$2.31

$-0.2200

-8.70%
Today's

SKYE

$2.31

$-0.2200

-8.70%

Skye Bioscience Inc

Skye Bioscience Inc shares dropped -8.70% today.

Skye Bioscience Inc operates under a business model focused on developing and commercializing innovative therapeutic treatments. The company primarily engages in research and development activities to discover novel drugs targeting specific medical conditions and diseases. Skye Bioscience Inc aims to generate revenue by successfully bringing these drugs to market through partnerships, licensing agreements, or direct sales.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 89.673 mill.	$ - mill.	$ -41.766 mill.	39 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 89.673 mill.	$ - mill.	$ -41.766 mill.
Employees	Shares Outstanding	P/E
9	39 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

TNGX

$1.785

$-0.1650

-8.46%
Today's

TNGX

$1.785

$-0.1650

-8.46%

Tango Therapeutics Inc

Tango Therapeutics Inc shares dropped -8.46% today.

Tango Therapeutics Inc is a biotechnology company that focuses on developing cancer therapies using DNA sequencing and computational biology. Their business model revolves around discovering and developing precision medicines by leveraging their expertise in genomics and biology to target specific cancer vulnerabilities.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 195.453 mill.	$ 42.069 mill.	$ -130.302 mill.	110 mill.	-	Y/Y -24.21 %

Market Cap.	Revenues TTM	Net Income TTM
$ 195.453 mill.	$ 42.069 mill.	$ -130.302 mill.
Employees	Shares Outstanding	P/E
60	110 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -24.21 %	MRQ Y/Y - %

VINC

$0.7598

$-0.0692

-8.35%
Today's

VINC

$0.7598

$-0.0692

-8.35%

Vincerx Pharma Inc

Vincerx Pharma Inc stock dropped -8.35% today.

Vincerx Pharma Inc*s business model is focused on developing and commercializing novel small molecule drugs for the treatment of cancer. They aim to leverage their scientific expertise and collaborations to identify and advance promising drug candidates, ultimately providing innovative therapies to patients in need.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 34.702 mill.	$ - mill.	$ -27.030 mill.	46 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 34.702 mill.	$ - mill.	$ -27.030 mill.
Employees	Shares Outstanding	P/E
17	46 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

JSPR

$5.179

$-0.4710

-8.34%
Today's

JSPR

$5.179

$-0.4710

-8.34%

Jasper Therapeutics Inc

Jasper Therapeutics Inc shares went down -8.34% today.

Jasper Therapeutics Inc operates in the biotechnology industry, focusing on developing stem cell-based therapies for hematopoietic and immune system disorders. Their business model involves utilizing innovative stem cell technologies and partnerships within the medical community to advance their research and bring potential treatments to patients in need.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 75.481 mill.	$ - mill.	$ -71.269 mill.	15 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 75.481 mill.	$ - mill.	$ -71.269 mill.
Employees	Shares Outstanding	P/E
24	15 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

UPB

$9.055

$-0.8150

-8.26%
Today's

UPB

$9.055

$-0.8150

-8.26%

Upstream Bio Inc

Upstream Bio Inc stock went down -8.26% today.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 123.971 mill.	$ 4.740 mill.	$ -139.340 mill.	14 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 123.971 mill.	$ 4.740 mill.	$ -139.340 mill.
Employees	Shares Outstanding	P/E
-	14 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

REVB

$2.76

$-0.2400

-8.00%
Today's

REVB

$2.76

$-0.2400

-8.00%

Revelation Biosciences Inc

Revelation Biosciences Inc shares went down -8.00% today.

Revelation Biosciences Inc*s business model focuses on developing innovative therapies and technologies for various medical conditions.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 0.473 mill.	$ - mill.	$ -15.039 mill.	0 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 0.473 mill.	$ - mill.	$ -15.039 mill.
Employees	Shares Outstanding	P/E
11	0 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

ELEV

$0.4843

$-0.0416

-7.91%
Today's

ELEV

$0.4843

$-0.0416

-7.91%

Elevation Oncology inc

Elevation Oncology Inc stock declined -7.91% today.

Elevation Oncology Inc*s business model focuses on precision medicine and targeted therapies for rare and genomically defined cancers.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 27.621 mill.	$ - mill.	$ -44.485 mill.	57 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 27.621 mill.	$ - mill.	$ -44.485 mill.
Employees	Shares Outstanding	P/E
82	57 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

IBIO

$4.48

$-0.3800

-7.82%
Today's

IBIO

$4.48

$-0.3800

-7.82%

Ibio inc

Ibio Inc stock dropped -7.82% today.

Ibio Inc is a plant-based biologics company that focuses on the development and manufacturing of therapeutic proteins. They utilize their proprietary plant-based expression system to produce biotherapeutics quickly and cost-effectively. By leveraging their platform, Ibio aims to address unmet medical needs and provide affordable and accessible treatments to patients worldwide.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 40.911 mill.	$ 0.375 mill.	$ -20.220 mill.	9 mill.	-	Y/Y 300.00 %

Market Cap.	Revenues TTM	Net Income TTM
$ 40.911 mill.	$ 0.375 mill.	$ -20.220 mill.
Employees	Shares Outstanding	P/E
14	9 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 300.00 %	MRQ Y/Y - %

DNTH

$20.345

$-1.6250

-7.40%
Today's

DNTH

$20.345

$-1.6250

-7.40%

Dianthus Therapeutics Inc

Dianthus Therapeutics Inc shares went down -7.40% today.

Dianthus Therapeutics Inc is a biotechnology company that focuses on developing novel genetic medicines for patients suffering from rare genetic diseases. Their business model revolves around leveraging cutting-edge gene therapy technologies to design and deliver innovative treatments. By partnering with academic institutions and utilizing a proprietary gene therapy platform, they aim to address unmet medical needs and provide potential new therapies for patients with genetic disorders.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 677.919 mill.	$ 6.235 mill.	$ -84.969 mill.	33 mill.	-	Y/Y -30.28 %

Market Cap.	Revenues TTM	Net Income TTM
$ 677.919 mill.	$ 6.235 mill.	$ -84.969 mill.
Employees	Shares Outstanding	P/E
14	33 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -30.28 %	MRQ Y/Y - %

ALLR

$0.8619

$-0.0661

-7.12%
Today's

ALLR

$0.8619

$-0.0661

-7.12%

Allarity Therapeutics Inc

Allarity Therapeutics Inc stock declined -7.12% today.

Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1.358 mill.	$ - mill.	$ -19.612 mill.	2 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 1.358 mill.	$ - mill.	$ -19.612 mill.
Employees	Shares Outstanding	P/E
12	2 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

PGEN

$1.655

$-0.1250

-7.02%
Today's

PGEN

$1.655

$-0.1250

-7.02%

Precigen Inc

Precigen Inc shares declined -7.02% today.

Precigen Inc is a biotechnology company that focuses on the development and commercialization of innovative genetic therapies. Their business model revolves around leveraging their proprietary technologies and expertise in gene editing and synthetic biology to create transformative medical solutions. With a strong emphasis on research and development, Precigen aims to bring cutting-edge genetic therapies to market and address critical unmet medical needs.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 456.583 mill.	$ -2.187 mill.	$ -139.564 mill.	276 mill.	-	Y/Y -30.89 %

Market Cap.	Revenues TTM	Net Income TTM
$ 456.583 mill.	$ -2.187 mill.	$ -139.564 mill.
Employees	Shares Outstanding	P/E
141	276 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -30.89 %	MRQ Y/Y - %

VOR

$0.8

$-0.0603

-7.01%
Today's

VOR

$0.8

$-0.0603

-7.01%

Vor Biopharma Inc

Vor Biopharma Inc stock went down -7.01% today.

Vor Biopharma Inc*s business model focuses on developing novel cell therapies for the treatment of cancer.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 54.773 mill.	$ - mill.	$ -112.463 mill.	68 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 54.773 mill.	$ - mill.	$ -112.463 mill.
Employees	Shares Outstanding	P/E
44	68 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

SDGR

$22.125

$-1.6050

-6.76%
Today's

SDGR

$22.125

$-1.6050

-6.76%

Schrodinger Inc

Schrodinger Inc shares went down -6.76% today.

Schrodinger Inc is a computational drug discovery company that utilizes physics-based solutions to accelerate the discovery and development of new drugs. Their business model involves providing software and services to pharmaceutical and biotechnology companies, enabling them to optimize and streamline their drug discovery processes. By leveraging their unique expertise in computational chemistry and molecular modeling, Schrodinger aims to empower their clients in the pursuit of efficient and effective drug development.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1,610.932 mill.	$ 207.539 mill.	$ -187.123 mill.	73 mill.	-	Y/Y 22.28 %

Market Cap.	Revenues TTM	Net Income TTM
$ 1,610.932 mill.	$ 207.539 mill.	$ -187.123 mill.
Employees	Shares Outstanding	P/E
400	73 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 22.28 %	MRQ Y/Y - %

RXRX

$6.39

$-0.4500

-6.58%
Today's

RXRX

$6.39

$-0.4500

-6.58%

Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc shares declined -6.58% today.

Recursion Pharmaceuticals Inc is a biotech company that utilizes its artificial intelligence (AI) platform to identify and develop potential drug candidates. They employ a unique approach by combining AI technology with experimental biology and automation to accelerate drug discovery. Recursion applies its platform to identify new treatments for rare diseases and have established partnerships with various organizations in the pharmaceutical industry.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 1,753.132 mill.	$ 58.839 mill.	$ -463.661 mill.	274 mill.	-	Y/Y -58.26 %

Market Cap.	Revenues TTM	Net Income TTM
$ 1,753.132 mill.	$ 58.839 mill.	$ -463.661 mill.
Employees	Shares Outstanding	P/E
400	274 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -58.26 %	MRQ Y/Y - %

OLMA

$4.16

$-0.2900

-6.52%
Today's

OLMA

$4.16

$-0.2900

-6.52%

Olema Pharmaceuticals Inc

Olema Pharmaceuticals Inc stock declined -6.52% today.

Olema Pharmaceuticals Inc.*s business model focuses on the research, development, and commercialization of innovative cancer therapies.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 238.213 mill.	$ - mill.	$ -122.679 mill.	57 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 238.213 mill.	$ - mill.	$ -122.679 mill.
Employees	Shares Outstanding	P/E
45	57 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

VERV

$5.91

$-0.4100

-6.49%
Today's

VERV

$5.91

$-0.4100

-6.49%

Verve Therapeutics Inc

Verve Therapeutics Inc stock went down -6.49% today.

Verve Therapeutics Inc is a biotechnology company specialized in developing transformative medicines that could permanently prevent cardiovascular diseases through gene editing technology. Their business model revolves around leveraging cutting-edge gene editing techniques to develop novel therapeutics targeting specific genes associated with heart diseases. By utilizing this approach, Verve aims to provide long-term solutions for individuals at risk of cardiovascular ailments, addressing a significant unmet need in the healthcare industry.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 499.732 mill.	$ 32.332 mill.	$ -198.709 mill.	85 mill.	-	Y/Y 154.28 %

Market Cap.	Revenues TTM	Net Income TTM
$ 499.732 mill.	$ 32.332 mill.	$ -198.709 mill.
Employees	Shares Outstanding	P/E
15	85 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 154.28 %	MRQ Y/Y - %

ANRO

$2.89

$-0.2000

-6.47%
Today's

ANRO

$2.89

$-0.2000

-6.47%

Alto Neuroscience Inc

Alto Neuroscience Inc stock dropped -6.47% today.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 77.912 mill.	$ - mill.	$ -94.966 mill.	27 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 77.912 mill.	$ - mill.	$ -94.966 mill.
Employees	Shares Outstanding	P/E
-	27 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

AGEN

$1.665

$-0.1150

-6.46%
Today's

AGEN

$1.665

$-0.1150

-6.46%

Agenus Inc

Agenus Inc shares went down -6.46% today.

Agenus Inc is a biotechnology company that primarily focuses on the discovery and development of immune-based therapies for cancer treatment. Their business model revolves around leveraging their proprietary technologies and capabilities to develop and commercialize therapeutic antibodies and vaccines. Agenus Inc also collaborates with other pharmaceutical companies through licensing agreements and partnerships to further advance their product pipeline.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 35.881 mill.	$ 160.428 mill.	$ -234.047 mill.	22 mill.	-	Y/Y 3.28 %

Market Cap.	Revenues TTM	Net Income TTM
$ 35.881 mill.	$ 160.428 mill.	$ -234.047 mill.
Employees	Shares Outstanding	P/E
114	22 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y 3.28 %	MRQ Y/Y - %

INMB

$7.18

$-0.4900

-6.39%
Today's

INMB

$7.18

$-0.4900

-6.39%

Inmune Bio Inc

Inmune Bio Inc stock dropped -6.39% today.

Inmune Bio Inc is a biotechnology company that focuses on developing innovative therapies for treating cancer and neurodegenerative diseases. Their business model revolves around conducting research and clinical trials to develop novel drug candidates targeting specific proteins involved in immune regulation and inflammation. They aim to license or partner their drug candidates with pharmaceutical companies for further development and commercialization, potentially generating revenue through licensing agreements or royalties.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 144.933 mill.	$ - mill.	$ -41.427 mill.	20 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 144.933 mill.	$ - mill.	$ -41.427 mill.
Employees	Shares Outstanding	P/E
15	20 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

IOBT

$0.8603

$-0.0587

-6.39%
Today's

IOBT

$0.8603

$-0.0587

-6.39%

Io Biotech Inc

Io Biotech Inc shares declined -6.39% today.

Io Biotech Inc*s business model focuses on the development and commercialization of innovative immuno-oncology therapies.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 56.677 mill.	$ - mill.	$ -90.340 mill.	66 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 56.677 mill.	$ - mill.	$ -90.340 mill.
Employees	Shares Outstanding	P/E
26	66 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %

DNA

$7.28

$-0.4900

-6.31%
Today's

DNA

$7.28

$-0.4900

-6.31%

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks Holdings Inc shares dropped -6.31% today.

Ginkgo Bioworks Holdings Inc is a biotechnology company that focuses on using genetic engineering to develop new organisms for various industries. Their business model includes partnering with companies to create custom-designed organisms for applications such as fragrance production, food and beverage, agriculture, and pharmaceuticals. They generate revenue through collaborations, licensing agreements, and providing access to their platform for organism design and development.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 377.834 mill.	$ 227.043 mill.	$ -547.029 mill.	52 mill.	-	Y/Y -20.90 %

Market Cap.	Revenues TTM	Net Income TTM
$ 377.834 mill.	$ 227.043 mill.	$ -547.029 mill.
Employees	Shares Outstanding	P/E
400	52 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y -20.90 %	MRQ Y/Y - %

RLAY

$3.29

$-0.2200

-6.27%
Today's

RLAY

$3.29

$-0.2200

-6.27%

Relay Therapeutics Inc

Relay Therapeutics Inc shares went down -6.27% today.

Relay Therapeutics Inc is a biotechnology company focused on developing targeted therapies for diseases by leveraging insights from protein motion. Their business model involves utilizing computational simulations and algorithms to discover and design small molecule therapies that can effectively target specific proteins involved in various diseases.

Market Cap.	Revenues TTM	Net Income TTM	Shares Outstanding	P/E	Revenue Growth
$ 470.788 mill.	$ - mill.	$ -337.708 mill.	143 mill.	-	Y/Y - %

Market Cap.	Revenues TTM	Net Income TTM
$ 470.788 mill.	$ - mill.	$ -337.708 mill.
Employees	Shares Outstanding	P/E
280	143 mill.	-
Revenue Growth	Income Growth
MRQ Y/Y - %	MRQ Y/Y - %